Loading clinical trials...
Loading clinical trials...
A Study To Evaluate The Efficacy Of Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy To Reduce Provoked Allergic Rhinitis Symptoms Using The Nasal Allergen Challenge Model
Conditions
Interventions
Dupilumab
Timothy Grass SCIT
+2 more
Locations
17
United States
Regeneron Investigational Site
Los Angeles, California, United States
Regeneron Investigational Site
Mountain View, California, United States
Regeneron Investigational Site
Walnut Creek, California, United States
Regeneron Investigational Site
Baltimore, Maryland, United States
Regeneron Investigational Site
Andover, Massachusetts, United States
Regeneron Investigational Site
North Dartmouth, Massachusetts, United States
Start Date
June 7, 2018
Primary Completion Date
May 14, 2019
Completion Date
June 13, 2019
Last Updated
May 28, 2020
NCT07419230
NCT06732414
NCT05494346
NCT07110311
NCT04815668
NCT06846385
Lead Sponsor
Regeneron Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions